



PAULA CARVALHO

Attorney at Law

+ 55 21 3550 3713
+ 55 21 99808 6656
paula.carvalho@lickslegal.com

PRACTICE AREAS

- Government Contracts & Public Procurements
- Litigation
- Regulatory Law
- Technology, Media & Telecommunications
- Regulatory
- Counseling and Transactional

LANGUAGES

- Portuguese
- English
- French

BIOGRAPHY

Paula Carvalho is an attorney at law at Licks Attorneys' Rio de Janeiro office since in 2020. Ms. Carvalho practice area has been focusing on administrative litigation and legal advice. Her experience includes advising clients in regulatory and external control matters, government tender consultations and proceedings, and government contracts. Prior to joining Licks Attorneys, Ms. Carvalho gained experience as an associate attorney at a prominent Brazilian law firm specialized in public law.

PROFESSIONAL HIGHLIGHTS

- Legal 500 Latin America – Key lawyer – Life Sciences (2025)

AFFILIATIONS

- Brazilian Bar Association – Rio de Janeiro (OAB/RJ).

EDUCATION

- Bachelor of Laws (LL.B.), Rio de Janeiro State University – UERJ (2018).

PUBLICATIONS

- [Lexology In-Depth: Healthcare Law - Edition 10 - Brazil](#), Lexology, 2026;
- [First Impressions of the New statute governing PDPs: Confusing Provisions and Risk of Reduced Competition](#), Lexology, 2026;
- [Primeiras impressões da nova lei das PDPs: Disposições confusas e risco de reserva de mercado](#), Migalhas, 2026;
- [Brazil reinstates preference margins for the procurement of medicines](#), Lexology, 2024;
- [Brasil volta a instituir margens de preferência para compra de medicamentos](#), JOTA, 2024;

- [Brazilian Federal Medical Board imposes stricter rules for transparency](#), Lexology, 2024;
- [Does Law 14,874 address the obstacles that prevented Brazil from becoming a hub for clinical research? - Part II](#), Lexology, 2024;
- [Lei 14.874 e obstáculos para Brasil virar hub de pesquisa clínica – parte 2](#), JOTA, 2024;
- [O STJ e a publicidade de medicamentos](#), JOTA, 2024;
- [Does Law #14,874 address the obstacles that prevented Brazil from becoming a hub for clinical research?](#), Lexology, 2024;
- [Lei 14.874 resolve obstáculos que impediam Brasil de virar hub de pesquisa clínica?](#), JOTA, 2024;
- [Mudanças na regulamentação da CGU da Lei Anticorrupção não garantem imparcialidade](#), Estadão, 2023;
- [How does CGU interpret the Brazilian Anticorruption Statute terms](#), 2023;
- [Como a CGU interpreta prazos da Lei Anticorrupção](#), Valor Econômico, 2023;
- [O desafio dos biossimilares e a postura do Ministério da Saúde no Brasil](#), Migalhas, 2021.